hugo biotech

Hugo Biotech was founded in early 2017, focusing on pathogen infection diagnosis based on nucleic acid detection technology. It is committed to applying cutting-edge technologies such as gene sequencing, big data analysis, and artificial intelligence in clinical medicine to help clinicians enhance their diagnostic capabilities for unknown pathogens, thereby enabling rapid and precise medical intervention. Since its inception, the China-U.S. team of Hugo Biotech has jointly chosen a distinctive technical route, and currently operates two research and development centers in China and abroad. Over the past four years, tens of thousands of clinical sequencing samples have shown that Hugo Biotech’s cost, quality control, and accuracy are significantly better than industry standards, accumulating a solid clinical reputation.